Efficacy of ESHAP versus ICE plus dexamethasone (DICE) as salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma

The results from a study of patients with relapsed/refractory DLBCL showed that the efficacy of second-line salvage chemotherapy with ESHAP (etoposide, methylprednisolone, cytarabine and cisplatin) compared with DICE (ifosfamide, carboplatin and etoposide plus dexamethasone) did not differ significantly. ORR was 47.6% vs 53.1% (p = .67), two-year PFS was 14.3% vs 26.5% (p = .33), and two-year OS was 14.3% vs 26.5% for DICE (p = .37), respectively.